In this online exclusive, Dr Andrew Rut, CEO of MyMeds&Me, a provider of adverse event and product quality capture software, discusses the value of big data for the pharma industry and the conflict that arises between protecting personal data and effective drug development.
Big Data
The recent introduction of stringent data regulation, and the hardening of attitudes to data privacy globally could have a significant impact on the pharmaceutical sector. While new technologies are enabling the capture of purer patient data at an unprecedented volume and rate, which is being used to accelerate and enhance research and development, the onus is on pharma companies to recognise the paramount importance of data protection by implementing ‘best practice’ systems.